期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

双类似物鼻黏膜耐受治疗实验性自身免疫性重症肌无力的免疫机制 被引量：1

The Therapeutic Effect of Nasal Tolerance with Dual Analogue on Experimental Autoimmune Myasthenia Gravis Rats
下载PDF
导出
摘要 目的　用双类似物鼻黏膜耐受治疗实验性自身免疫性重症肌无力 ( EAMG)大鼠 ,探讨其对机体免疫机制的影响。方法　建立 Lewis大鼠的 EAMG模型 ,在致敏同时 ( A组 )及缓解期第 1天 ( B组 )给予双类似物 3 0 0μg/只。动态评估大鼠临床症状 ,检测外周血 ( PB) ACh R-Ab( Ig G)含量 ,检测急、慢性期 PB单个核细胞 ( MNC)及致敏第 5 0天淋巴结、脾 MNC中的 CD4+ CD2 5 + 细胞数改变。结果　治疗组大鼠临床症状减轻 ;治疗组及对照组大鼠 PB中特异性 ACh R-Ab( Ig G)含量随病程延续而增加 ,但在致敏后第 5及第 7周 ,A、B组特异性 Ig G抗体含量比各自对照组显著减低 ( P <0 .0 5 ) ;双类似物鼻黏膜耐受治疗后 ,EAMG大鼠 PB MNC中的 CD4+ 细胞数减少 ( P<0 .0 5 ) ,CD4+ CD2 5 +细胞数相对增加 ( P<0 .0 5 ) ;A、B组淋巴结和脾 MNC中 CD4+细胞数减少( P<0 .0 5 ) ,CD4+ CD2 5 +细胞数只在 B组相对增加 ( P <0 .0 5 )。结论　双类似物鼻黏膜耐受治疗病情进展中的 EAMG有效 ;伴随临床症状缓解 ,治疗组大鼠 ACh R-Ab( Ig G)含量减少且免疫调节性 CD4+ CD2 5 +细胞数相对增多 ;双类似物治疗 EAMG的可行性为抗原特异性治疗重症肌无力 ( MG)和其他自身免疫性疾病 ( AID)提供了依据。 Objective To study the therapeutic effect of nasal tolerance with a dual analogue (Lys262-Ala207) on experimental autoimmune myasthenia gravis (EAMG) and to elucidate the underlying immune mechanism, in Lewis rats treated with dual analogue. Methods 300 μg/rat of dual analogues was given to Lewis rats immunized with acetylcholine receptor (AChR) in complete Freund adjuvant(CFA) at two different time points and the clinical symptoms were evaluated. Then the amount of anti-AChR IgG in serum were tested by ELISA, while the numbers of CD4+ CD25+ cells from blood, lymphocyte and spleen were tested by flow cytometry. Results Lewis rats receiving dual analogue nasally for 10 consecutive days at the time of immuniza-tion or on the first day after complete remission from acute phase of the disease developed EAMG all were with reduced severity. Compared with their respective control groups, the group A and group B had decreased amount of anti-AChR IgG in the 5th and 7th weeks.While the absolute reduction of CD4 T cells (P<0.05) and relatively increased numbers of CD4+ CD25+ cells from blood (P<0.05), lymph node and spleen (P<0.05) were observed. Conclusions Nasal tolerance induced by a dual analogue Lys-262-Ala-207 can treat clinical EAMG and modulate the immune function of EAMG rats. This gives light to mucosal administration of dual analogue as an alternative maneuver in human myasthenia gravis (MG).
作者 王丽华 富羽弘 王化冰 王维治
机构地区 中国人民解放军 哈尔滨医科大学附属第二医院神经科
出处 《中国神经免疫学和神经病学杂志》 CAS 2003年第3期197-200,207,共5页 Chinese Journal of Neuroimmunology and Neurology
基金 国家自然科学基金资助项目 ( 3 9970 2 62)
关键词 实验性自身免疫性重症肌无力 鼻黏膜耐受 双类似物 experimental autoimmune myasthenia gravis nasal tolerance dual analogue
分类号 R746.1 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献9

  • 1Lennon VA,Lambert EH,Leiby KR,et al. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis[J]. J Immunol, 1991,146:2245-2248.
  • 2Seddon B,Mason D. The third function of the thymus[J]. Immunol Today, 2000,21(1):95-98.
  • 3Takahashi TY,Kuniyasu M,Toda N,et al. Immunologic self-tolerance maintained by CD4+CD25+ naturally anergic and suppressive T cells: induction of autoimmune diseases by breaking their anergic/suppressive state[J]. Int Immunol,1998,10:1969-1071.
  • 4Shevach EM,McHugh RS,Piccirillo CA,et al. Control of T cell activation by CD4+CD25+ suppressor T cells[J]. Immunol Rev, 2001,128:58-67.
  • 5Suto A,Nakajima H,Ikeda K,et al. CD4+CD25+ T cell development is regulated by at least 2 distinct mechanisms[J]. Blood, 2002,99(2):555-560.
  • 6Zhang X,Izikson L,Liu L,et al. Activation of CD25+CD4+ regulatory T cells by oral antigen administration[J]. J Immunol, 2001,167(8):4245-4253.
  • 7Melamed D,Fredman A. In vivo tolerization of Th1 lymphocytes following a single feeding with ovalbumin: anergy in the absence of suppression[J]. Eur J Immunol, 1994,24:1974-1981.
  • 8王维治,王丽宏,杨秋霞,杨春娥.实验性自身免疫性脑脊髓炎豚鼠鼻粘膜免疫耐受研究[J].中华神经科杂志,1999,32(6):329-331. 被引量：8
  • 9富羽弘,王化冰,王维治,王丽华.双类似物鼻粘膜耐受对实验性自身免疫性重症肌无力的影响[J].中华神经科杂志,2002,35(6):365-369. 被引量：7

二级参考文献12

  • 1王维治.神经系统自身免疫病的口服免疫耐受[J].医学进展,1997,2:5-9.
  • 2王维治，医学进展，1997年，2卷，5页
  • 3Ma C G，Ann New York Acad Sci，1996年，788卷，273页
  • 4Sun J B，Proc Nat Acad Sci USA，1996年，93卷，7196页
  • 5Dick A D，Immunol，1994年，82卷，625页
  • 6Conti-Fine BM, Navaneetham D, Karachunski PI, et al. T cell recognition of the acetylcholine receptor in myasthenia gravis. Ann N Acad Sci, 1998, 841:283-308.
  • 7Wang HB, Shi FD, Li H, et al. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol, 2001, 166:6430-6436.
  • 8Lennon VA, Lambert EH, Leiby KR, et al. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol, 1991, 146:2245-2248.
  • 9Paas-Rozner M, Dayan M, Paas Y, et al. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice. Proc Natl Acad Sci USA, 2000, 97:2168-2173.
  • 10Paas-Rozner M,Sela M, Mozes E. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. Proc Natl Acad Sci USA, 2001, 98:12642-12647.

共引文献13

同被引文献17

  • 1Aruna BV, Sela M, Mozes E. Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4+ CD25 + regulatory cells. Proc Natl Acad Sci U S A, 2005, 102: 10285-10290.
  • 2Paas-Rozner M, Dayan M, Paas Y, et al. Oral administration of a dual of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice. Proc Natl Acad Sci U S A, 2000, 97: 2168-2173.
  • 3Aruna BV, Sela M, Mozes E. Down-regulation of T cell responses to AChR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4 + CD25 + regulatory cells. J Neuroimmunol, 2006, 177 : 63-75.
  • 4Paas-Rozner M, Sela M, Mozes E. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. Proe Natl Aead Sci U S A, 2001, 98: 12642- 12647.
  • 5Faber-Elmann A, Grabovsky V, Dayan M, et al. Cytokine profile and T cell adhesiveness to endothelial selectins: in vivo induction by a myasthenogenic T cell epitope and immunomodulation by a dual altered peptide ligand. Int Immunol, 2000, 12: 1651-1658.
  • 6Dayan M, Sthoeger Z, Neiman A, et al. Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravis. Hum Immunol, 2004, 65: 571-577.
  • 7Faber-Elmann A, Grabovsky V, Dayan M, et al. An altered peptide ligand inhibits the activities of matrix metallopreteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM- 1 induced in vivo by a myasthenogenic T cell epitope. FASEB J, 2001, 15 : 187-194.
  • 8Paas-Rozner M, Sela M, Mozes E. A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4+ T ceils. Proc Natl Acad Sci U S A, 2003, 100: 6676-6681.
  • 9Fattorossi A, Battaglia A, Buzzonetti A, et al. Circulating and thymic CD4CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology, 2005, 116: 134- 141.
  • 10Balandina A, Lecart S, Dartevelle P, et al. Functional defect of regulatory CD4( + )CD25 + T cells in the thymus of patients with autoimmune myasthenia gravis. Blood, 2005, 105 : 735- 741.

引证文献1

中国神经免疫学和神经病学杂志
2003年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部